Clinical Trials Browser

Phase 1 × camrelizumab × 90 days × Clear all

NCT06654297 2026-04-02

Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas

Phase 1 Active not recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma